Category: AdvanTIG-302 Trial - Medicine Pharmacy Nutrition

No Image

BeiGene Reports First Patient Dosing in P-III AdvanTIG-302 Trial of Ociperlimab (BGB-A1217) + Tislelizumab (BGB-A317) to Treat Non-Small Cell Lung Cancer

June 18, 2021 Auto Bot 0

Shots: The first patient has been dosed in global P-III AdvanTIG-302 trial evaluating ociperlimab + tislelizumab in 605 naïve patients with locally advanced, unresectable, or […]

Copyright © 2022 | WordPress Theme by MH Themes

Azərbaycan dili

Беларуская мова

বাংলা

Български

ქართული

Ελληνικά

ગુજરાતી

Ōlelo Hawaiʻi

עִבְרִית

हिन्दी

Bahasa Indonesia

ಕನ್ನಡ

Қазақ тілі

ភាសាខ្មែរ

Кыргызча

ພາສາລາວ

Latviešu valoda

Lietuvių kalba

Lëtzebuergesch

Македонски јазик

മലയാളം

मराठी

ဗမာစာ

नेपाली

ਪੰਜਾਬੀ

Српски језик

සිංහල

தமிழ்

తెలుగు

Українська